Andreas Weichselberger

4.3k total citations · 3 hit papers
20 papers, 3.3k citations indexed

About

Andreas Weichselberger is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Andreas Weichselberger has authored 20 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Ophthalmology, 10 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Andreas Weichselberger's work include Retinal Diseases and Treatments (13 papers), Retinal Imaging and Analysis (9 papers) and Retinal and Optic Conditions (8 papers). Andreas Weichselberger is often cited by papers focused on Retinal Diseases and Treatments (13 papers), Retinal Imaging and Analysis (9 papers) and Retinal and Optic Conditions (8 papers). Andreas Weichselberger collaborates with scholars based in Switzerland, United States and Germany. Andreas Weichselberger's co-authors include Ursula Schmidt‐Erfurth, Reinier O. Schlingemann, Francesco Bandello, Paul Mitchell, Pascale Massin, Christian Simader, Frank G. Holz, Pravin U. Dugel, Gabriela Burian and Gabriele E. Lang and has published in prestigious journals such as Diabetes Care, Ophthalmology and Investigative Ophthalmology & Visual Science.

In The Last Decade

Andreas Weichselberger

19 papers receiving 3.1k citations

Hit Papers

The RESTORE Study 2010 2026 2015 2020 2011 2019 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The RESTORE Study
    2011 1.0k citations Paul Mitchell, Francesco Bandello et al. Ophthalmology profile →
  2. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
    2019 623 citations Pravin U. Dugel, Adrian Koh et al. Ophthalmology profile →
  3. Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
    2010 566 citations Pascale Massin, Francesco Bandello et al. Diabetes Care profile →

Peers

Andreas Weichselberger
Alyson J. Berliner United States
Cynthia R. Stockdale United States
Mark Michels United States
Chirag Jhaveri United States
Hemal Mehta United Kingdom
J.M.M. Groenewoud Netherlands
Marla B. Sultan United States
Wen-Hsiang Lee United States
Hee Jung Kwon South Korea
Chieko Takagi Japan
Alyson J. Berliner United States
Andreas Weichselberger
Citations per year, relative to Andreas Weichselberger Andreas Weichselberger (= 1×) peers Alyson J. Berliner

Countries citing papers authored by Andreas Weichselberger

Since Specialization
Citations

This map shows the geographic impact of Andreas Weichselberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Weichselberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Weichselberger more than expected).

Fields of papers citing papers by Andreas Weichselberger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Weichselberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Weichselberger. The network helps show where Andreas Weichselberger may publish in the future.

Co-authorship network of co-authors of Andreas Weichselberger

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Weichselberger. A scholar is included among the top collaborators of Andreas Weichselberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Weichselberger. Andreas Weichselberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dugel, Pravin U., Adrian Koh, Yuichiro Ogura, et al.. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 127(1). 72–84. 623 indexed citations breakdown →
2.
3.
Dugel, Pravin U., et al.. (2018). Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER. Investigative Ophthalmology & Visual Science. 59(9). 1455–1455. 2 indexed citations
4.
Poor, Stephen, et al.. (2018). Topical VEGF receptor inhibitor, LHA510, did not demonstrate efficacy in a Proof-of-Concept study in patients with neovascular age-related macular degeneration (nv AMD). 59(9). 2394–2394. 5 indexed citations
5.
Dugel, Pravin U., Glenn J. Jaffe, Peter Sallstig, et al.. (2017). Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 124(9). 1296–1304. 179 indexed citations
6.
Holz, Frank G., Pravin U. Dugel, Georges Weissgerber, et al.. (2016). Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration. Ophthalmology. 123(5). 1080–1089. 133 indexed citations
7.
Dugel, Pravin U., James Warburton, Andreas Weichselberger, & Peter Sallstig. (2016). A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen. 57(12). 5018–5018. 4 indexed citations
8.
Waldstein, Sebastian M., Victor Chong, Michael Larsen, et al.. (2016). Association of fluid recurrence with visual maintenance following the loading phase in anti-VEGF therapy for neovascular AMD. 57(12). 533–533. 2 indexed citations
9.
Singerman, Lawrence J., Andreas Weichselberger, & Peter Sallstig. (2015). OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Investigative Ophthalmology & Visual Science. 56(7). 4801–4801. 7 indexed citations
10.
Berger, Brian B., Susan E. Yanni, Andreas Wenzel, Andreas Weichselberger, & Jean‐Pierre Hubschman. (2015). Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD. 56(7). 821–821. 4 indexed citations
11.
Holz, Frank G., Winfried M. K. Amoaku, J. Donate-López, et al.. (2011). Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study. Ophthalmology. 118(4). 663–671. 315 indexed citations
12.
Wolf, Sebastián, Frank G. Holz, Korobelnik Jf, et al.. (2011). Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology. 95(12). 1713–1718. 12 indexed citations
13.
Mitchell, Paul, Francesco Bandello, Ursula Schmidt‐Erfurth, et al.. (2011). The RESTORE Study. Ophthalmology. 118(4). 615–625. 1031 indexed citations breakdown →
14.
Lanzetta, Paolo, Gabriela Burian, Andreas Weichselberger, & Yehia Hashad. (2010). Safety Profiles of Diabetic versus Non-Diabetic AMD Patients in Randomized Controlled Clinical Studies With Ranibizumab. Investigative Ophthalmology & Visual Science. 51(13). 91–91. 2 indexed citations
15.
Schmidt‐Erfurth, Ursula, Bora Eldem, Robyn H. Guymer, et al.. (2010). Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. Ophthalmology. 118(5). 831–839. 316 indexed citations
16.
Holz, Frank G., Jean‐François Korobelnik, Paolo Lanzetta, et al.. (2010). The Effects of a Flexible Visual Acuity–Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model. Investigative Ophthalmology & Visual Science. 51(1). 405–405. 56 indexed citations
17.
Massin, Pascale, Francesco Bandello, Justus G. Garweg, et al.. (2010). Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). Diabetes Care. 33(11). 2399–2405. 566 indexed citations breakdown →
18.
19.
Tomšič, Matija, et al.. (2005). Evaluation of Pimecronlimus Tablets 30 mg Bid for the Treatment of Dry Eye in Primary Sjögren’s Syndrome Patients. Investigative Ophthalmology & Visual Science. 46(13). 2025–2025. 1 indexed citations
20.
Ousler, George W, et al.. (2005). Comparison of Pimecrolimus 1%, 0.3% and 0.1% With Vehicle for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model. 46(13). 2031–2031. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alyson J. Berliner Breakdown of academic impact, for papers by Cynthia R. Stockdale Breakdown of academic impact, for papers by Mark Michels Breakdown of academic impact, for papers by Chirag Jhaveri Breakdown of academic impact, for papers by Hemal Mehta Breakdown of academic impact, for papers by J.M.M. Groenewoud Breakdown of academic impact, for papers by Marla B. Sultan Breakdown of academic impact, for papers by Wen-Hsiang Lee Breakdown of academic impact, for papers by Hee Jung Kwon Breakdown of academic impact, for papers by Chieko Takagi
Rankless by CCL
2026